報價延遲最少15分鐘:2025/07/09 20:20 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.59 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.90/-2.12
|
|
企業價值
403.15M
|
| 資產負債 |
|
每股賬面淨值
2.06
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/09 20:20 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States. |